Eric Hobbs - May 11, 2022 Form 4 Insider Report for Berkeley Lights, Inc. (CELL)

Role
President - Antibody Therapeutics
Signature
/s/ Christine Nassi, Attorney-in-fact for Eric Hobbs
Stock symbol
CELL
Transactions as of
May 11, 2022
Transactions value $
-$952,003
Form type
4
Date filed
5/13/2022, 07:53 PM
Previous filing
Mar 22, 2022
Next filing
May 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CELL Common Stock Options Exercise $833 +1.3K +0.35% $0.64 374K May 11, 2022 Direct
transaction CELL Common Stock Options Exercise $24K +37.5K +10.03% $0.64 411K May 11, 2022 Direct
transaction CELL Common Stock Sale -$410K -98K -23.83% $4.18* 313K May 11, 2022 Direct F1, F2
transaction CELL Common Stock Sale -$530K -123K -39.28% $4.31* 190K May 12, 2022 Direct F1, F3
transaction CELL Common Stock Sale -$37.4K -7.53K -3.96% $4.97* 183K May 13, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CELL Stock Option (Right to Buy) Options Exercise $0 -1.3K -100% $0.00* 0 May 11, 2022 Common Stock 1.3K $0.64 Direct F4
transaction CELL Stock Option (Right to Buy) Options Exercise $0 -37.5K -100% $0.00* 0 May 11, 2022 Common Stock 37.5K $0.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.66. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option is currently exercisable.

Remarks:

President - Antibody Therapeutics